...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>British Journal of Haematology >Immune dysregulation and dyserythropoiesis in the myelodysplastic syndromes.
【24h】

Immune dysregulation and dyserythropoiesis in the myelodysplastic syndromes.

机译：骨髓增生异常综合症中的免疫调节异常和促红细胞生成异常。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The myelodysplastic syndromes (MDS) are clonal disorders characterised by ineffective haematopoiesis with high risk of leukaemia progression. The relevance of immune-dysregulation for emergence, dominance and progression of dysplastic clones has been suggested, but valuable criteria to obtain insight into these connections are lacking. This study showed significant increase of CD8 lymphocytes and mature B cells in the bone marrow (BM) compared to peripheral blood (PB) of low risk MDS patients. Different BM levels of Regulatory T cells (Treg) identified two sub-groups in these patients; only the sub-group with lower Treg percentage showed BM recruitment of CD8 lymphocytes. Different levels of CD54 on BM CD8 cells revealed two sub-groups of Intermediate-1 (Int-1) patients. The sub-group with higher CD54 expression on BM CD8 showed high levels of this molecule also on CD4 cells. BM recruitment of CD8 lymphocytes in the low risk group and/or the presence of high CD54 expression on BM CD8 in Int-1 patients were associated with more pronounced dyserythropoiesis and erythropoietin treatment. Our data shed light on the involvement of immune-mediated mechanisms in Low and Int-1 risk MDS patients and suggest that BM versus PB levels of immune effectors could represent useful criteria for a more homogeneous grouping of MDS patients.
机译：骨髓增生异常综合症（MDS）是克隆性疾病，其特征在于无效的造血功能和白血病进展的高风险。已经提出免疫异常调节与发育异常克隆的出现，优势和进展的相关性，但是缺乏深入了解这些联系的有价值的标准。这项研究表明，与低危MDS患者的外周血（PB）相比，骨髓（BM）中的CD8淋巴细胞和成熟B细胞显着增加。在这些患者中，不同的BM调节性T细胞（Treg）水平确定了两个亚组。仅Treg百分比较低的亚组显示出CD8淋巴细胞的BM募集。 BM CD8细胞上不同水平的CD54揭示了两个亚组的中级1（Int-1）患者。在BM CD8上具有较高CD54表达的亚组在CD4细胞上也显示出高水平的该分子。低风险组的BM募集CD8淋巴细胞和/或Int-1患者的BM CD8上CD54高表达，与更明显的促红细胞生成素和促红细胞生成素治疗相关。我们的数据阐明了低和Int-1风险MDS患者中免疫介导机制的参与，并表明免疫效应物的BM与PB水平可能代表MDS患者更均一分组的有用标准。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号